NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer because no evidence submission was received from the manufacturer or sponsor of the technology.

This appraisal relates to the treatment of wild-type KRAS metastatic colorectal cancer for first-line treatment in combination with FOLFOX, and for second-line treatment in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).


Since the publication of TA240, the population covered by the marketing authorisation for panitumumab has changed from ‘patients with wild-type KRAS metastatic colorectal cancer’ to ‘patients with wild-type RAS metastatic colorectal cancer’

March 2015

  • National Institute for Health and Care Excellence (NICE) accreditation logo